January 16, 2018Journal of the American Academy of DermatologyOpen Access

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

View Full Paper

Ask AI

Bookmark

Abstract

When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Simpson et al. (2018) studied this question.

synapsesocial.com/papers/69dad66a4e9a02dbaa684ac6 https://doi.org/10.1016/j.jaad.2018.01.017

View Full Paper

Ask AI

Bookmark

Abstract

When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Abstract

Discussion

Cite This Study

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Abstract

Discussion

Cite This Study

Keep reading

Keep reading